Clinical Report: A Smart Gradient-Directed Hybrid Inpainting Approach for Reconstructing Brain MRI

Overview

This study presents a novel gradient-guided hybrid inpainting framework that combines classical and deep learning methods for reconstructing brain MRI images. The proposed method significantly improves reconstruction accuracy and maintains structural fidelity, which is crucial for Alzheimer's disease classification.

Background

Alzheimer's disease (AD) is a leading cause of dementia, making early and accurate diagnosis essential for effective treatment. Brain MRI is a vital tool in diagnosing AD, but clinical scans often suffer from artifacts that can obscure critical anatomical details. Improving MRI image quality through advanced inpainting techniques can enhance diagnostic accuracy and support automated classification systems.

Data Highlights

Key Findings

• The hybrid inpainting framework combines OpenCV Telea and LaMa methods.
• Gradient magnitude-based weighting enhances structural fidelity in reconstructions.
• Mean squared error is reduced by 8% compared to LaMa and 30% compared to OpenCV.
• A VGG16 classifier achieves 94.35% accuracy on hybrid-inpainted data.
• The proposed method shows minimal performance drop compared to baseline methods.

Clinical Implications

Discuss potential integration strategies for the hybrid inpainting method in clinical settings.

Conclusion

The proposed gradient-guided hybrid inpainting framework demonstrates significant improvements in MRI reconstruction and classification accuracy for Alzheimer's disease, highlighting its potential for enhancing AI-driven neuroimaging pipelines.

Related Resources & Content

1. npj Digital Medicine, 2025 -- An Efficient CVTC Framework for Precise MRI Evaluation and Lesion Marking in Alzheimer’s Disease
2. Frontiers in Medicine, 2026 -- Advances in AI-based diagnosis of Alzheimer’s disease using MRI: a comprehensive survey
3. European Radiology, 2025 -- Deep Learning-Based Synthesis of MRI and PET for Quantifying Amyloid-β in Alzheimer’s Disease
4. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup - PMC
5. European Radiology — Artificial Intelligence-Driven Segmentation of Brain and Cerebrospinal Fluid Volume Alterations Associated with Aging
6. FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)
7. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup - PMC
8. Lecanemab in Early Alzheimer’s Disease | New England Journal of Medicine
9. Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities - PMC